Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Furmonertinib as First-Line Therapy in EGFR-Mutant PD-L1-Positive NSCLC
ChiCTR2300076542Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of toripalimab and furmonertinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by West China Hospital of Sichuan University. Primary endpoints: Dose-limiting toxicity, Progression-free survival and 2 more. Started Nov 2023; status: recruiting.
02
Drugs
toripalimabfurmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300076542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076542.